An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions
- Sponsors Novartis
- 16 Oct 2017 Planned End Date changed from 30 Oct 2018 to 4 Oct 2023.
- 13 Oct 2015 Planned End Date changed from 1 Dec 2018 to 1 Oct 2018 as per ClinicalTrials.gov record.
- 13 Oct 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Oct 2018 as per ClinicalTrials.gov record.